Skip to main content
SpringerLink
Log in

Evaluation of fludarabine phosphate in malignant melanoma

A Southwest Oncology Group study

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Twenty-seven evaluable patients with advanced malignant melanoma received fludarabine phosphate in a daily × 5 injection. Initial dosing was based on the presence of previous radiation therapy. There was no response seen in these patients despite appropriate dose escalation. Myelosuppression occurred without significant sequelae.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wagner DE, et al.: (COG) Combination Phase I–II study of imidazole carboxamide (NSC-45388). Oncology 26:310–6, 1972

    Google Scholar 

  2. Fludarabine Phosphate (2-FAMP) NSC 312887. National Cancer Institute Brochure, November, 1982

  3. Cass CE, Au-Yeung TH: Enhancement of 9-beta-Darabino-furanosyladenine cytotoxicity to mouse leukemia L1210 in vitro by 2′-deoxycoformycin. Cancer Res 36:1486–1491, 1976

    Google Scholar 

  4. Casper ES, Mittelman A, Kelson D, Young CW: Phase I clinical trial of fludarabine phosphate (F-ara-AMP). Cancer Chemother Pharmacol 15:233–235, 1985

    Google Scholar 

  5. Kuhn J, Von Hoff DD, et al.: Phase I trial of 2-fluoro-ara-AMP (NSC 312887). Fourth NCI-EORTC Symposium on New Drugs in Cancer Therapy, Brussels, December, 1983

Download references

Author information

Authors and Affiliations

  1. Wayne State University Medical Center, Detroit, MI, USA

    Julie A. Kish & Michael K. Samson

  2. Southwest Oncology Group Statistical Center, Seattle, W A, USA

    Ken Kopecky

  3. University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

    Daniel D. Von Hoff

  4. Oregon Health Sciences University, Portland, OR, USA

    William S. Fletcher

  5. University of Southern California School of Medicine, Los Angeles, CA, USA

    Raymond A. Kempf & Franco M. Muggia

Authors
  1. Julie A. Kish
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ken Kopecky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael K. Samson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniel D. Von Hoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. William S. Fletcher
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Raymond A. Kempf
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Franco M. Muggia
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Address for offprints: Southwest Oncology Group (SWOG-8324), Operations Office, 5430 Fredericksburg Road, Suite #618, San Antonio, TX 78229-6197, USA

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kish, J.A., Kopecky, K., Samson, M.K. et al. Evaluation of fludarabine phosphate in malignant melanoma. Invest New Drugs 9, 105–108 (1991). https://doi.org/10.1007/BF00194559

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00194559

Key words

Search

Navigation